EP-1130: Hair-sparing whole brain radiotherapy with simultaneous integrated boost using high density bolus  by Velázquez Miranda, S. et al.
ESTRO 35 2016                                                                                                                                                    S541 
________________________________________________________________________________ 
Conclusion: Sequential chemotherapy and radiotherapy in 
adult medulloblastoma/PNET tumors is feasible with 
acceptable toxicity. High relapse rate in our patients indicate 
the need of treatment intensification with better 
coordination of combined therapy. 
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Purpose or Objective: Glioma is a primary brain tumour 
arising from the glial cells. High grade glioma, defined as 
grade III and IV, have poor survival rates. Glioblastoma 
multiforme is the commonest, but is also, the most 
aggressive type of glioma and is associated with a poor 
prognosis. Median survival of patients after treatment with 
debulking surgery followed by concurrent chemoradiotherapy 
and adjuvant chemotherapy is 14.6 months. Currently, post-
operative fractionated radiotherapy is prescribed to a range 
of 54 to 60 Gy in fractions of 2 Gy.  
Organs at risk (OARs) including optic chiasm, optic nerves and 
the brain stem, may lie within, or in close proximity to the 
PTV. Neuropathy and/or necrosis has been shown to occur 
when the maximum dose exceeds 55Gy in the optic chiasm 
and 54Gy to the whole brainstem. The standard practice at 
Rosemere Cancer Centre is to prioritise the OARs at the 
expense of the total dose, therefore prescribing to a dose of 
54Gy whenever the OARs is included in the PTV, which may 
have repercussions on tumour control and ultimately, overall 
survival.  
This retrospective analysis aims to compare patient outcomes 
between the 54Gy/57Gy and 59.4Gy/60Gy regimes, to 
determine if compromising the dose to spare OARs is 
detrimental to tumour control and survival. 
 
Material and Methods: The data of all glioma patients 
treated with radiotherapy between December 2012 and 
December 2014 at Rosemere Cancer Centre, were collected 
from our electronic databases. A total of 167 patients were 
identified. Patients with low grade glioma and those treated 
with a palliative intent were excluded. Fifty eight patients 
were included in the analysis. 
 
Results: Twenty one patients were on a lower dose 
radiotherapy regime of 54Gy or 57Gy. The remaining 37 were 
on a higher dose regime of 59.4Gy or 60Gy. There was a 
statistically significant difference (p=0.05) in patients treated 
with the higher dose regime comparatively, of an additional 
7.2 months median overall survival (mOS) benefit. The 
mortality hazard for the higher dose regime is 37% lower than 
the lower dose regime. 
 
Conclusion: The outcome of patients treated with the 
59.4/60Gy dose regime has shown to be statistically 
significant with a mOS benefit and lower mortality hazard. It 
is therefore clear that maintenance of the higher dose 
(59.4/60Gy) should be a priority, either at the expense of the 
OARs or to as much of the tumour volume as possible, whilst 
still observing the OARs constraints. 
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Purpose or Objective: Collateral irradiation of normal 
structures during whole brain radiotherapy increases the risk 
of secondary toxicities, including dysfunction of the 
hypothalamic-pituitary axis (HPA). In studies of children 
treated for intracranial neoplasms, Merchant et al. showed 
that upwards of 66% of patients had pre-irradiation 
endocrinopathies and that HPA dosimetry data can be used to 
predict the dose-volume effects of radiation on growth 
hormone (GH) secretion. However, no comparable endocrine 
studies have been performed in adult populations. Evidence 
exists to suggest that hypopituitarism is an independent risk 
factor for mortality in adults treated with whole brain 
radiotherapy. Increased collaboration between radiation 
oncologists and endocrinologists is needed to amalgamate 
dosimetry data with the results of endocrine testing and 
better characterize HPA dysfunction. The purpose of this 
study is to determine the presence of baseline HPA 
dysfunction as well as the time to onset and dose-
dependence of post-irradiation HPA dysfunction in adults 
treated for non-pituitary brain tumours. 
 
Material and Methods: Twelve patients, 3 males and 9 
females, have been enrolled in our prospective clinical study 
that will continue to recruit until 2017. Primary diagnoses 
included meningioma (7), pineal tumor (3), and glioma (2). 
Median patient age is 52 (range 23-71). Enrolled patients 
have undergone comprehensive baseline endocrine testing of 
the thyroid, gonadotropins, cortisol, prolactin, and GH prior 
to initiation of radiotherapy. Patients have received daily 
image guidance imaging with positional correction and 50-60 
Gy of radiation to the tumour bed. Parametisation of 
available dosimetry data was performed to determine the 
maximum, minimum, and mean radiation doses. Endocrine 
testing is being repeated at 6 month intervals following 
radiotherapy. Patient reported outcome measures are also 
collected during follow-up encounters. Reviewing 
endocrinologists have been blinded to dosimetry data. 
 
Results: Three patients (25%) demonstrated pre-irradiation 
endocrinopathies, including 2 cases of primary 
hypothyroidism and 1 case of primary hypogonadism. 
Furthermore, one patient exhibited temporary HPA 
suppression secondary to exogenous steroid use. Median 
length to endocrinology follow-up is still short at only 3 
months (range 0-18). We present analyzed dose data for 10 of 
the 12 patients. Mean radiation doses to the hypothalamus 
and pituitary were 35 Gy (range 20-55) and 31 Gy (range 13-
50), respectively. No cases of new, radiation-related HPA 
dysfunction have been identified to date. 
 
Conclusion: The incidence of pre-irradiation HPA dysfunction 
underlines the need for baseline endocrinology studies. The 
range of radiation doses to the HPA should allow for 
identification of dose-volume responses.  
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Purpose or Objective: Present and retrospectively evaluate 
our protocol of WBRT + SIB regarding radiation-induced 
alopecia 
 
Material and Methods: We use masks type 35764 / 2MA / M 
Orfit a subnet mask with eXaskin and compatible base 
resonance (eXaFrame). A similar number of slices is used in 
the images of CT and MRI, both acquisitions with identical 
position and immobilization and slice thickness of 1 mm. This 
is possible thanks to eXaFrame, resulting in excellent quality 
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fusion. The treatment was designed with SmartArc with 
multiple arches made with Synergy. The dosage regimen used 
is Lagerwaard one: [RCT (20 Gy) + SIBmts (40 Gy)] / 5 frac. 
Positioning of the patient was checked daily with conebeam. 
Before starting the optimization we must be contoured 3mm 
ring around the calote we call follicles, and a contraction of 
the outer contour of 12mm we call volume CPE. We define 
two arcs (VMAT CCW 178 ° -60 ° and 300 ° -182 °), with the 
following objectives: follicles (DSEmax = 16 Gy, weight = 20; 
DSEmax = 5 Gy, weight = 1), brain-CPE (Dmax = 21Gy, weight 
= 100 and Dmin = 20 Gy, weight = 50), eyes (Dmax = 10 Gy, 
weight = 1). Later, we focus on separate metastases: 
optimization blocked prophylaxis (Optimization Type None) 
and create three structures: VI1 = PTV (MTS1) 5 mm VI2 = 
PTV (m2) 5 mm Epx = brain-VI1-VI2 . The objectives were 
PTVI (Dmax = 44Gy, despite Dmin = 100 and = 40 Gy weight = 
50), Epx (Dmax = 30 Gy) and brainstem (Dmax = 23Gy), 
follicles (DSEmax = 16 Gy, weight = 20 ; DSEmax = 5 Gy, 
weight = 1)  
Verifying treatment was performed with the Compass 
software, and the Matrixx detector with gamma (4%, 1 mm) 
conditioning. 
 
Results: So far we have treated 15 patients, the differences 
in the images of fusion of less than 1 mm and the average 
correction IGRT of 1.24mm. No acute toxicity. Nor alopecia, 
or temporary removal, 
 
Conclusion: If we consider our VMAT optimization alopecia in 
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Purpose or Objective: To describe clinical outcomes of 
hypofractionated radiotherapy, either in combination or not 
with temozolomide (TMZ) in poor performance status 
glioblastoma (GBM) patients 
 
Material and Methods: We retrieved the charts of 96 patients 
treated with hypofractionated radiotherapy plus/minus TMZ 
for GBM at our Institution 
 
Results: Patients characteristics were summarized in Table 1.  
 
 
Among elderly patients, 38 (71.6%) were treated with RT 
alone, 9 patients (16.9%) with adjuvant TMZ, while 6 patients 
(11.3%) with a KPS ≥70 received hypoRT plus concurrent TMZ, 
followed by adjuvant chemotherapy in 3 (5.6%) of these 
cases. The median follow up time of the entire cohort was 
13.6 months (range 1-47 months). A significant improvement 
in KPS from baseline to the end of radiation therapy was 
observed in 73 patients (76%). The median overall survival 
time was 6.7 months, reducing to only 2.5 months and 4 
months respectively in elderly and younger patients with low 
performance status (KPS<70). The 6 months and 1 year 
survival rates were respectively 56.4% and 29.1%. In 
multivariate analysis, concomitant Temozolomide (HR:0.38, 
95% CI 0.16-0.85,p=.020) and adjuvant TMZ (HR:0.28,95% CI 
0.14-0.56,p=.000) emerged as significant indices of longer OS 
rates, while weaning from steroids (p=.18), extent of surgical 
resection (p=.17) and tumor site (p=.10) were not significant 
predictors of overall survival but showed a positive trend. 
Patients who received concomitant TMZ had a median 
survival time of 12.5 months compared with 6.3 months for 
those treated with RT alone (p=.017). Also the use of 
adjuvant chemotherapy resulted in improved survival 
compared to no sequential Temozolomide (10.8 vs 5.2 
months, p=.001). In the elderly cohort, patients treated with 
adjuvant TMZ had median OS of 8.15 months as opposed to 
6.4 months of those not receiving adjuvant chemotherapy 
(p=.001). A stronger impact of adjuvant TMZ has been 
reported in younger patients, with a median OS of 13.5 
months in adjuvant TMZ group compared to 3.7 months 
(p=.001) in the other group. Moreover, younger patients 
receiving concurrent Temozolomide showed a significantly 
longer OS of 20 months compared to 5.1 months in patients 
not having TMZ (p=.006). Acute tolerance to radiotherapy 
was generally good. No grade 3-4 acute toxicity was 
observed. 
 
Conclusion: Our findings seem to suggest that frail elderly 
patients with KPS at baseline < 70 do not benefit of an active 
treatment and could be carefully offered best supportive 
care. In the presence of a good functional status and a wide 
surgical resection, patients older than 65 years may take 
advantage of hypo-fractionated radiotherapy, followed by 
adjuvant TMZ. In younger patients with poor performance 
status, the significant survival gains obtained with combined 
modality treatment suggest that a maximum resection 
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Purpose or Objective: Assessment of tolerance of combined 
modality therapy of patients with malignant gliomas 
irradiated using IMRT technique. We compared dose 
distribution in IMRT and conformal 3D treatment plans. 
 
Material and Methods: Between 2009 and 2013 in the 
Oncology Center in Krakow 60 patients with malignant 
gliomas received combined modality treatment. Mean age 
was 53 years (range 24–72 years). All patients were in good 
performance status (WHO 0–1). There were 48 patients with 
glioblastoma multiforme and 12 with anaplastic astrycytoma. 
48 patients underwent complete resection and 12 partial 
resection. Patient were irradiated using IMRT technique with 
a total dose of 60Gy in 30 fractions. All patients concurrently 
received temozolamide in the dose of 75mg/m2. In all 
patients we performed additional plans using 3D conformal 
